Analyst Reco. Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
3.71 ^USD	+0.54%		-0.27%	+21.64%

03-27	Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	CI
02-28	Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Downgrades Atea Pharmaceuticals to Underweight From Neutral	10/08/23	MT
JPMorgan Adjusts Atea Pharmaceuticals Price Target to $8 From $12, Maintains Neutral Rating	16/03/23	MT
SVB Securities Adjusts Atea Pharmaceuticals' Price Target to $6 From $8, Keeps Market Perform Rating	27/01/23	MT
Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $4 From $7, Maintains Underweight Rating	24/01/23	MT
Morgan Stanley Raises Atea Pharmaceuticals' Price Target to $7 From $6, Maintains Underweight Rating	15/08/22	MT
JPMorgan Adjusts Price Target for Atea Pharmaceuticals to $8 From $10, Maintains Neutral Rating	02/03/22	MT
SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $9 from $10, Keeps Market Perform Rating	01/03/22	MT
SVB Leerink Adjusts Atea Pharmaceuticals' Price Target to $10 from $11, Maintains Market Perform Rating	16/02/22	MT
Morgan Stanley Adjusts Atea Pharmaceuticals Price Target to $6 From $7, Reiterates Underweight Rating	01/02/22	MT
Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight From Equal Weight, Adjusts PT to $7 From $14	06/01/22	MT
SVB Leerink Downgrades Atea Pharmaceuticals to Market Perform From Outperform, Sets $11 Price Target	18/11/21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Atea Pharmaceuticals PT to $14 From $55, Maintains Equal Weight Rating	20/10/21	MT
ATEA PHARMACEUTICALS : SVB Leerink Adjusts Atea Pharmaceuticals PT to $20 From $60, Maintains Outperform Rating	20/10/21	MT
ATEA PHARMACEUTICALS : JPMorgan Downgrades Atea Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $16 from $61	20/10/21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Downgrades Atea Pharmaceuticals to Equalweight From Overweight, Boosts Price Target to $55 From $37	05/10/21	MT
ATEA PHARMACEUTICALS : SVB Leerink Starts Atea Pharmaceuticals at Outperform with $60 Price Target	09/09/21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $37 From $35, Maintains Overweight Rating	18/08/21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Atea Pharmaceuticals to $35 From $82, Maintains Overweight Rating	03/06/21	MT
Roche : Eyes New Location For COVID-19 Pill Study As UK Infection Rate Falls	21/04/21	MT
ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Atea Pharmaceuticals' Price Target to $82 from $49, Keeps Overweight Rating	06/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Analyst Reco.

Filters